Single Molecule Sequencing
Mobious’ proprietary sequencing and expression analysis should help make it economically viable to undertake research into understanding and addressing diseases at the genetic level. Indeed, one of the company’s earliest goals was to develop a process capable of determining individual whole genome sequences in a day or less, at commercially sustainable levels. We regard this as the foundation of a new era in healthcare and will seek strategic partnerships to enable us to achieve this objective.
Currently, there is no commercially feasible technology that will enable the direct and accurate i.e. down to base-pair resolution, comparison of human whole genome sequences. The time and cost involved using current techniques would make even a single comparison unfeasible. Furthermore, in the case of aggressive disease states, any patient could well have died before such analysis was complete. The impact of such ultra-fast whole genome sequencing on the understanding of human disease and on the global healthcare landscape would be immense.
There are significant bottlenecks at every stage of current sequencing technologies. These can be traced back to the fundamental restrictions that severely limit the ultimate throughput, resulting in high levels of redundancy and unsatisfactory operational economics.
Mobious has taken a fundamentally different approach. The key component was to learn from nature. Our solution pivots on the same process responsible for the propagation of all life; cell division. Our technology is capable of potentially limitless read lengths and sequencing from a minute DNA sample. We have combined this with vastly accelerated processing to produce a system that has the potential for individual whole genome sequencing at commercially viable costs.
The critical problem in sequencing a genome today is akin to attempting to reassemble a telephone directory from 10 copies torn into tiny pieces (due to the fact that current technologies must "amplify" the amount of DNA from the sample in order to work).
This is because existing, "state-of-the art", sequencing machines can only read short stretches of DNA. Hence the genome must first be broken into small pieces, which not only greatly increases the number of samples required and hence the level of redundancy (increasing associated costs and processing time) but the complexity of the data obtained. Such approaches involve greater computer software, hardware and operator costs and reduce the value of the data itself.
The very long read length of Mobious’ technology (analogous to reading many pages to the phone book at once) will reduce the complexity and cost of processing data, while simultaneously reducing redundancy and cost.
Mobious’ proprietary sequencing and expression analysis should help make it economically viable to undertake research into understanding and addressing diseases at the genetic level. Indeed, one of the company’s earliest goals was to develop a process capable of determining individual whole genome sequences in a day or less, at commercially sustainable levels. We regard this as the foundation of a new era in healthcare and will seek strategic partnerships to enable us to achieve this objective.
Currently, there is no commercially feasible technology that will enable the direct and accurate i.e. down to base-pair resolution, comparison of human whole genome sequences. The time and cost involved using current techniques would make even a single comparison unfeasible. Furthermore, in the case of aggressive disease states, any patient could well have died before such analysis was complete. The impact of such ultra-fast whole genome sequencing on the understanding of human disease and on the global healthcare landscape would be immense.
There are significant bottlenecks at every stage of current sequencing technologies. These can be traced back to the fundamental restrictions that severely limit the ultimate throughput, resulting in high levels of redundancy and unsatisfactory operational economics.
Mobious has taken a fundamentally different approach. The key component was to learn from nature. Our solution pivots on the same process responsible for the propagation of all life; cell division. Our technology is capable of potentially limitless read lengths and sequencing from a minute DNA sample. We have combined this with vastly accelerated processing to produce a system that has the potential for individual whole genome sequencing at commercially viable costs.
The critical problem in sequencing a genome today is akin to attempting to reassemble a telephone directory from 10 copies torn into tiny pieces (due to the fact that current technologies must "amplify" the amount of DNA from the sample in order to work).
This is because existing, "state-of-the art", sequencing machines can only read short stretches of DNA. Hence the genome must first be broken into small pieces, which not only greatly increases the number of samples required and hence the level of redundancy (increasing associated costs and processing time) but the complexity of the data obtained. Such approaches involve greater computer software, hardware and operator costs and reduce the value of the data itself.
The very long read length of Mobious’ technology (analogous to reading many pages to the phone book at once) will reduce the complexity and cost of processing data, while simultaneously reducing redundancy and cost.